AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Mineralys Therapeutics Statistics
Share Statistics
Mineralys Therapeutics has 49.77M shares outstanding. The number of shares has increased by 0.28% in one year.
Shares Outstanding | 49.77M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.08% |
Owned by Institutions (%) | n/a |
Shares Floating | 23.55M |
Failed to Deliver (FTD) Shares | 1 |
FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 1.59M, so 3.19% of the outstanding shares have been sold short.
Short Interest | 1.59M |
Short % of Shares Out | 3.19% |
Short % of Float | 6.74% |
Short Ratio (days to cover) | 9.24 |
Valuation Ratios
The PE ratio is -4.33 and the forward PE ratio is -3.86.
PE Ratio | -4.33 |
Forward PE | -3.86 |
PS Ratio | 0 |
Forward PS | 31.4 |
PB Ratio | 1.29 |
P/FCF Ratio | -3.83 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Mineralys Therapeutics Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.76, with a Debt / Equity ratio of 0.
Current Ratio | 23.76 |
Quick Ratio | 23.76 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.3% and return on capital (ROIC) is -35.1%.
Return on Equity (ROE) | -0.3% |
Return on Assets (ROA) | -0.29% |
Return on Capital (ROIC) | -35.1% |
Revenue Per Employee | 0 |
Profits Per Employee | -2.57M |
Employee Count | 28 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 4.84% in the last 52 weeks. The beta is 2.46, so Mineralys Therapeutics 's price volatility has been higher than the market average.
Beta | 2.46 |
52-Week Price Change | 4.84% |
50-Day Moving Average | 12.56 |
200-Day Moving Average | 12.54 |
Relative Strength Index (RSI) | 27.81 |
Average Volume (20 Days) | 205.78K |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -84.66M |
Net Income | -71.90M |
EBITDA | -84.66M |
EBIT | n/a |
Earnings Per Share (EPS) | -1.99 |
Balance Sheet
The company has 49.30M in cash and 0 in debt, giving a net cash position of 49.30M.
Cash & Cash Equivalents | 49.30M |
Total Debt | 0 |
Net Cash | 49.30M |
Retained Earnings | -124.71M |
Total Assets | 268.25M |
Working Capital | 236.41M |
Cash Flow
In the last 12 months, operating cash flow was -81.17M and capital expenditures 0, giving a free cash flow of -81.17M.
Operating Cash Flow | -81.17M |
Capital Expenditures | 0 |
Free Cash Flow | -81.17M |
FCF Per Share | -2.24 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
MLYS does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -21.87% |
FCF Yield | -17.92% |
Analyst Forecast
The average price target for MLYS is $30, which is 229.7% higher than the current price. The consensus rating is "Buy".
Price Target | $30 |
Price Target Difference | 229.7% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Scores
Altman Z-Score | 9.94 |
Piotroski F-Score | 1 |